D-3,4-二氯苯丙氨酸 | 52794-98-6

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 苯丙氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: D-3,4-二氯苯丙氨酸
• 中文别名: D-3,4-二氯-L-苯丙氨酸；H-D-Phe(3,4-DiCl)-OH；3,4-二氯-D-苯丙氨酸
• 英文名称: (R)-2-amino-3-(3,4-dichlorophenyl)propanoic acid
• 英文别名: 3,4-dichloro-D-phenylalanine；D-3,4-dichloro-Phe；D-3,4-diCl-Phe；(2R)-2-amino-3-(3,4-dichlorophenyl)propanoic acid
• CAS: 52794-98-6
• 化学式: C₉H₉Cl₂NO₂
• 分子量: 234.082
• InChiKey: NRCSJHVDTAAISV-MRVPVSSYSA-N

物化性质

• 沸点：
  370.6±42.0 °C(Predicted)
• 密度：
  1.450±0.06 g/cm3(Predicted)
• 溶解度：
  溶于氯仿、二氯甲烷、乙酸乙酯、DMSO、丙酮等。

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  67.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2922499990

反应信息

• 作为反应物：
  描述：

  D-3,4-二氯苯丙氨酸 在 lithium hydroxide 、 sodium hydroxide 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 10.5h， 生成 (S)-1-[(R)-3-(3,4-Dichloro-phenyl)-2-phenylmethanesulfonylamino-propionyl]-pyrrolidine-2-carboxylic acid (2-amino-thiazol-4-ylmethyl)-amide
  参考文献：
  名称：

  Discovery of a Novel, Selective, and Orally Bioavailable Class of Thrombin Inhibitors Incorporating Aminopyridyl Moieties at the P1 Position

  摘要：

  A novel class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position has been discovered. Four of these thrombin inhibitors (13b,c,e and 14d) showed nanomolar potency (K-i 0.8-12 nM), 300-1500-fold selectivity for thrombin compared with trypsin, and good oral bioavailability (F = 40-76%) in rats or dogs. The neutral Fl was expected to increase metabolic stability and oral absorption. Identification of this novel aminopyridyl group at Fl was a key step in our search for a clinical candidate.

  DOI：

  10.1021/jm970493r
• 作为产物：
  描述：

  3,4-二氯苯丙氨酸 在 sodium hydroxide 、 氧气 、 三羟甲基氨基甲烷 作用下， 以 水 为溶剂， 反应 22.0h， 以45%的产率得到D-3,4-二氯苯丙氨酸
  参考文献：
  名称：

  Enantioselective scavenging using homogenate of Rhodotorula graminis: a facile preparation of d-amino acid derivatives in enantiopure form

  摘要：

  An enantioselective scavenger (ES) comprised homogenate of Rhodotorula graminis containing multiple enzymes can enantioselectively remove L-enantiomer in a racemic mixture of amino acid derivatives (AADs), yielding D-enantiomer in high ee. Thirteen non-proteinogenic AADs were produced in enantiopure D form. The method appears to be an efficient cleaning and preparative strategy which can be applied to the production Of D-AADs in high ee by enantioselectively scavenging the 'L-contaminants'. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2008.08.111

文献信息

• [EN] AZASULFURYLPEPTIDE-BASED CD36 MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS CD36 À BASE D'AZASULFURYLPEPTIDES ET UTILISATIONS DE CEUX-CI
  申请人：RSEM LTD PARTNERSHIP

  公开号：WO2016029324A1

  公开（公告）日：2016-03-03

  Novel azasulfuryl-containing peptidomimetics capable of inhibiting CD36 activity are disclosed. Use of these azasulfuryl-containing peptidomimetics for the treatment of CD36-related diseases, disorders or conditions, including TLR2-mediated inflammatory disease, disorder or condition, and methods of obtaining such azasulfuryl-containing peptidomimetics, are also disclosed.

  揭示了能够抑制CD36活性的新型含氮硫酰基的肽类模拟物。还揭示了利用这些含氮硫酰基的肽类模拟物治疗与CD36相关的疾病、紊乱或状况，包括TLR2介导的炎症性疾病、紊乱或状况的用途，以及获取这种含氮硫酰基的肽类模拟物的方法。
• Lipid probes and uses thereof
  申请人：THE SCRIPPS RESEARCH INSTITUTE

  公开号：US10168342B2

  公开（公告）日：2019-01-01

  Disclosed herein are methods, compositions, probes, assays and kits for identifying a lipid binding protein as a drug binding target. Also disclosed herein are methods, compositions, and probes for mapping a ligand binding site on a lipid binding protein, identification of lipid binding proteins, generating drug-lipid binding protein profiles, high throughput drug screening, and identification of drugs as potential lipid binding protein ligands.

  披露了用于识别脂质结合蛋白作为药物结合靶点的方法、组合物、探针、检测和试剂盒。此外，还披露了用于绘制脂质结合蛋白上的配体结合位点、识别脂质结合蛋白、生成药物-脂质结合蛋白轮廓、高通量药物筛选以及识别作为潜在脂质结合蛋白配体的药物的方法、组合物和探针。
• [EN] TARGETED PLASMA PROTEIN DEGRADATION<br/>[FR] DÉGRADATION CIBLÉE DE PROTÉINES DE PLASMA
  申请人：NOVARTIS AG

  公开号：WO2021156792A1

  公开（公告）日：2021-08-12

  The present invention is directed to the bifunctional compounds and the use of such bifunctional compounds to lower plasma levels of extracellular target molecules by lysosomal degradation. Such bifunctional compounds have a cell surface receptor ligand covalently linked to a ligand that is capable of binding to an extracellular target molecule (such as a ligand for a growth factor, a cytokine, a chemokine, a hormone, a neurotransmitter, a capsid, a soluble receptor, an extracellular secreted protein, an antibody, a lipoprotein, an exosome, a virus, a cell, or a plasma membrane protein), where the cell surface receptor is associated with receptor mediated endocytosis, including asialoglycoprotein receptor (ASGPR) mediated lysosomal degradation and mannose-6-phosphate (M6PR) mediated lysosomal degradation. Pharmaceutical compositions comprising such bifunctional compounds and methods of treating a disease or disorder mediated by an extracellular molecule using such bifunctional compounds are also provided herein.

  本发明涉及双功能化合物及利用这种双功能化合物通过溶酶体降解降低细胞外靶分子血浆水平的用途。这种双功能化合物具有与细胞表面受体配体共价连接的配体，该配体能够结合到细胞外靶分子（例如生长因子、细胞因子、趋化因子、激素、神经递质、外壳蛋白、可溶性受体、细胞外分泌蛋白、抗体、脂蛋白、外泌体、病毒、细胞或血浆膜蛋白的配体），其中细胞表面受体与受体介导的内吞作用相关联，包括以阿斯利康蛋白受体（ASGPR）介导的溶酶体降解和甘露糖-6-磷酸（M6PR）介导的溶酶体降解。本文还提供了包括这种双功能化合物的药物组合物以及利用这种双功能化合物治疗通过细胞外分子介导的疾病或紊乱的方法。
• CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS
  申请人：Obrecht Daniel

  公开号：US20120202821A1

  公开（公告）日：2012-08-09

  Conformationally restricted, spatially defined 12-30 membered macrocyclic ring systems of type (I) are constituted by three distinct building blocks: an aromatic template a, a conformation modulator b and a spacer moiety c as detailed in the description and the claims. Macrocycles of type (I) are readily manufactured by parallel synthesis or combinatorial chemistry. They are designed to interact with specific biological targets. In particular, they show agonistic or antagonistic activity on the motilin receptor (MR receptor), on the serotonin receptor of subtype 5-HT 2B (5-HT 2B receptor), and on the prostaglandin F2•receptor (FP receptor). They are thus potentially useful for the treatment of hypomotility disorders of the gastrointestinal tract such as diabetic gastroparesis and constipation type irritable bowl syndrome; of CNS related diseases like migraine, schizophrenia, psychosis or depression; of ocular hypertension such as associated with glaucoma and preterm labour.

  构象受限、空间定义的12-30环大环环系统(I型)由三个不同的构建模块组成：芳香模板a、构象调节剂b和间隔基团c，如详细描述和索赔中所述。类型(I)的大环可通过并行合成或组合化学方法轻松制备。它们被设计用于与特定生物靶点相互作用。特别是，它们在胃动素受体(MR受体)、5-HT2B亚型的5-羟色胺受体(5-HT2B受体)和前列腺素F2受体(FP受体)上显示出激动或拮抗活性。因此，它们潜在地可用于治疗胃肠道低动力障碍，如糖尿病性胃轻瘫和便秘型肠易激综合征；中枢神经系统相关疾病，如偏头痛、精神分裂症、精神病或抑郁症；眼压增高，如青光眼和早产。
• Dimerization of Phenylalanine: An Approach to Thiazoles and Oxazoles Involved S/O-Insertion
  作者：Yan Cheng、Jia-Chen Xiang、Zi-Xuan Wang、Jin-Tian Ma、Miao Wang、Bo-Cheng Tang、Yan-Dong Wu、Yan-Ping Zhu、An-Xin Wu

  DOI：10.1002/adsc.201701130

  日期：2018.2.1

  We herein describe the development of a dimerization procedure for amino acids to prepare 2,5‐disubstituted thiazoles and oxazoles in the presence of Na2S⋅9H2O and H2O, respectively. These approaches enabled the direct formation of five‐membered ring systems bearing two different heteroatoms from two amino acid units. Mechanically, decarboxylation, deamination, S/O insertion, cyclization and gradient

  本文中，我们描述一个二聚化过程的发展，为氨基酸以制备钠的存在下2,5-二取代的噻唑和恶唑2 S⋅9H 2氧，氢2，分别O操作。这些方法能够直接形成带有两个氨基酸单元中两个不同杂原子的五元环系统。在机械上，脱羧，脱氨基，S / O插入，环化和梯度氧化过程涉及低聚物的形成。